Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation

Not Applicable

Terminated

• Conditions: Atrial Fibrillation
• Interventions: Procedure: Atrial Fibrillation Ablation; Procedure: Atrial Fibrillation Ablation with HD mapping to isolate PVs; Device: Catheters used to isolate pulmonary veins; Device: Rhythmia HD mapping

• Registration Number: NCT02917044
• Lead Sponsor: Imperial College Healthcare NHS Trust

Brief Summary

This is a prospective, multicentre, randomized single blind, parallel group study to be conducted in the UK (2 sites).Approximately 48 patients will be recruited aiming for 40 eligible for randomization. The study is designed to compare the operator's best attempt at WACA completion with and without Rhythmia guidance

Detailed Description

BACKGROUND Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia occurring in 1-2% of the general population. AF can be associated with debilitating symptoms and confers an increased risk of death, stroke, heart failure and hospitalization. As such there is a need for effective therapies for AF. In particularly catheter based therapies, which can limit the need for chronic drug therapy, are becoming more widely accepted.

The development of AF requires both a trigger and susceptible substrate. Ectopic activity originating within the pulmonary veins (PVs) is a widely recognised factor in the genesis of paroxysmal AF, whilst electrical, contractile and structural remodelling of atrial myocardium are each important contributing factors to the arrhythmogenic substrate in AF.

An early strategy in paroxysmal AF (PAF) was to target ectopic triggers coming from the PV via ostial segmental ablation (OSA). Here radiofrequency (RF) ablation was applied close to the PV ostia at sites of early signals, usually until PVs were electrically isolated from the left atrium (LA). This approach resulted in a success rate, with regard to freedom from AF after a single procedure, of 65-90% after 1 year but closer to 50% after 5 years. The recognition of PV stenosis as a complication of RF delivery within a PV, as well as the recognition that initiation sites could be located in the antrum led to a shift in ablation strategy towards wider encirclement of the PVs using wide area circumferential ablation (WACA) using electroanatomical mapping to guide RF delivery. This resulted in improved success rates in a head-to-head comparison with OSA and it is possible that this relates to substrate modification inherent in this approach.

Recurrence of AF remains problematic following ablation. Pulmonary vein reconnection after ablation is thought to contribute to the majority of recurrent episodes of AF in paroxysmal AF. Electrical isolation of the PVs is often not achievable with WACA alone - 95% of patients had residual connections following WACA alone in one study. Most clinicians at this juncture will look for any obvious gaps in the line and ablate if there are early PV signals. If this is unsuccessful then it is often necessary to resort to OSA to achieve PV isolation. In essence a large proportion of PV isolation procedures, which started with a WACA strategy, are in fact a hybrid of WACA and OSA. This both has the potential to increase the complication rate by risking PV stenosis and reducing efficacy through omitting important substrate modification and allowing residual connection of part of the antrum and the LA.

The introduction of Rhythmia, a novel electroanatomical mapping system with the potential to rapidly acquire high density electroanatomical data, may allow an alternative strategy and more efficient targeting of gaps in WACA lines. The pilot data shows that the system is particularly adept in assessing gaps in ablation lines including WACA lines. Mapping and targeting such gaps may hold the key to efficiently completing PV isolation after an initial WACA line is performed.

RATIONALE FOR CURRENT STUDY Research Question: Can ostial segmental ablation be avoided during a wide area circumferential ablation (WACA) by using the Rhythmia high density mapping system? Hypothesis: The current study is designed to test the hypothesis that high density mapping using Rhythmia can enhance the operator's ability to electrically isolate PVs without unnecessary excessive ablation or OSA

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2016-08-05
• Study First Submitted QC: 2016-09-27
• Study First Posted: 2016-09-28
• Primary Completion: 2018-03
• Study Completion: 2018-06
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-04
• Last Update Posted: 2019-10-08

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

• ECG documented AF
• Listed for AF ablation by referring physician
• Planned ablation includes a first-time PVI.
• Patient signed informed consent form

Read More

Exclusion Criteria

• Age <18 or >80
• LA diameter >60mm
• AF secondary to transient correctible abnormalits (e.g. electrolyte imbalance, thyrotoxicosis, recent infective or inflammatory process)
• Intra-atrial thrombus or tumour
• Renal failure requiring haemodialysis
• Heart failure with NYHA III-IV or EF<35%

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B - Rhythmia mapping	Atrial Fibrillation Ablation with HD mapping to isolate PVs	The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
Group A - Standard Care	Atrial Fibrillation Ablation	The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
Group B - Rhythmia mapping	Rhythmia HD mapping	The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
Group A - Standard Care	Catheters used to isolate pulmonary veins	The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
Group B - Rhythmia mapping	Catheters used to isolate pulmonary veins	The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.

Primary Outcome Measures

Name	Time	Method
Total time in minutes required to produce isolation of veins per WACA	Procedural - i.e. assessed over procedure duration only (about 3 hours)	Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total RF time taken to isolate the veins for that WACA will be measured as one of 2 joint primary outcome measures.
Total number of radiofrequency ablation lesions to produce isolation of veins per WACA	Procedural - i.e. assessed over procedure duration only (about 3 hours)	Following first pass ablation with WACA, if either vein is not isolated the patient will be randomized into group A or B. The total number of lesions (each lesion being 30s in duration) to isolate the veins for that WACA will be measured as one of two joint primary outcome measures.

Secondary Outcome Measures

Name	Time	Method
Percentage of patients with successful PV isolation	Procedural - i.e. assessed over procedure duration only (about 3 hours)	Proportion of veins successfully isolated with the contrasting techniques
Percentage of patients suffering symptomatic PV stenosis	3 months	Proportion of patients coming back within 3 months with symptomatic PV stenosis
Whether ostial ablation is required in each case (Yes/No)	Procedural - i.e. assessed over procedure duration only (about 3 hours)	This is a measure of whether ostial ablation (undesirable) will be required (yes/no). It is assessed during procedure.
Number of radiofrequency ablation lesions required within the WACA lesion set	Procedural - i.e. assessed over procedure duration only (about 3 hours)	The number of oostial lesions required in each case (number of ablation lesions)
Total procedural time (in mins) required to produce PV isolation	Procedural - i.e. assessed over procedure duration only (about 3 hours)	Whether procedure time (in mins) is different in group A vs group B
Percentage of patients with AF recurrence	3 months	Proportion of patients remaining AF free at 3 months as analysed per Kaplan-Meier format
Total radiofrequency ablation time (in mins) within the WACA lesion set	Procedural - i.e. assessed over procedure duration only (about 3 hours)	This is the total ablation time (in mins) within the WACA required to produce PV isolation
Total number of radiofrequency ablation lesions required to produce PV isolation per patient	Procedural - i.e. assessed over procedure duration only (about 3 hours)	As per primary endpoint but on a per patient rather than per vein basis

Trial Locations

Locations (1)

Hammersmith Hospital; 🇬🇧 London, Please Select Region, State Or Province, United Kingdom